Compare Adaptive Biotechnologies Corp (ADPT) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs JPMorgan Chase & Co — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while JPMorgan Chase & Co trades at $333.82 (market cap $908.94B). The key difference: JPMorgan Chase & Co is far larger — about 273× Adaptive Biotechnologies Corp's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | JPM | |
|---|---|---|
Market Cap | $3.33B | $908.94B |
Sector | Health | Financials |
52-Week High | $22.37 | $339.22 |
52-Week Low | $10.24 | $282.78 |
Enterprise Value | $3.19B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
JPMorgan Chase (JPM) trades at $332.64, down 1.5% on the day, as investors await Q2 2026 earnings results. The stock maintains a bullish technical outlook with strong moving average support and shows solid fundamentals with $181.85B revenue and 31.61% net income margin for 2025. Recent earnings beats in Q1 2026 ($5.94 vs $5.47 expected) demonstrate operational strength, while analyst consensus remains positive with a $360.38 price target.
JPMorgan presents a compelling investment case with industry-leading 17.03% ROE and reasonable 16.24 P/E valuation. Near-term catalysts include upcoming earnings and dividend payment, though risks persist from geopolitical tensions, cybersecurity threats, and CEO Dimon's warnings about economic challenges. The stock offers stability with institutional support but faces headwinds from interest rate sensitivity and global economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
